Biotech News

Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies (TSHA)Taysha Gene TherapiesEarnings

REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027 TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across

Related news

Taysha Gene Therapies

CNS Gene Therapy Focus Taysha Gene Therapies develops adeno-associated virus gene therapies for severe monogenic diseases of the central nervous system. Its strategy centers on one-time treatments intended to address the underlying genetic cause of disease. Lead Rett Syndrome Program TSHA-102 is an intrathecally delivered AAV9 gene...

Recent company news

Stock data

Close
3.77 USD
Market cap
1.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States